A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD
Starting soon · Phase 3 · Has a placebo group
Conditions studied: COPD (Chronic Obstructive Pulmonary Disease)
In brief
The purpose of this study is to evaluate the efficacy and safety of HSK39004 Inhalation Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Key facts
- Study ID
- NCT07658339
- Run by
- Haisco Pharmaceutical Group Co., Ltd.
- People needed
- 387
- Starts
- 2026-07-11
- Expected to finish
- 2027-06-11
- Last updated by the study team
- 2026-06-22
Who can join
Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Peking University Third Hospital — Beijing, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.